FDA Approval of Non-Opioid Pain Medication Suzetrigine

SOURCE www.foxnews.com
The Trump administration is addressing the fentanyl crisis. A new non-opioid pain medication called Suzetrigine has been approved by the FDA, offering an alternative for patients with acute pain. The medication aims to reduce dependency on opioids and prevent chronic pain. It is expected to be included in the NOPAIN Act effective January 2025.

Key Points

  • Suzetrigine is the first non-opioid oral pain signal inhibitor approved by the FDA
  • It works on pain receptors outside the brain, reducing the risk of addiction
  • Expected to be covered under the NOPAIN Act starting January 2025

Pros

  • Provides a non-addictive alternative for patients with acute pain
  • Reduces dependency on opioids
  • May prevent acute pain from developing into chronic pain

Cons

  • Possible side effects like itching, muscle spasms, and fertility challenges
  • Interaction with certain medications and foods like grapefruit